- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06348576
Phase III Study to Evaluate the Efficacy and Safety of AD-209
April 1, 2024 updated by: Addpharma Inc.
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of AD-209
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
Condition or disease : hypertension
Study Type
Interventional
Enrollment (Estimated)
280
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Kyung Tae Kim, D.V.M
- Phone Number: 82-031-891-5661
- Email: ktkim@addpharma.co.kr
Study Contact Backup
- Name: Chang Gyu Park, M.D., Ph.D
Study Locations
-
-
-
Seoul, Korea, Republic of
- Korea University Guro Hospital
-
Contact:
- Chang Gyu Park, M.D., Ph.D
-
Principal Investigator:
- Chang Gyu Park, M.D., Ph.D
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Signed informed consent
- Other inclusions applied
Exclusion Criteria:
- Orthostatic hypotension with symptom
- Other exclusions applied
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test group
AD-209+AD-2091 Placebo
|
PO, Once daily(QD), 8weeks
PO, Once daily(QD), 8weeks
|
Active Comparator: Control group
AD-2091+AD-209 Placebo
|
PO, Once daily(QD), 8weeks
PO, Once daily(QD), 8weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change rate of MSSBP
Time Frame: Baseline, Week 8
|
Change from baseline in mean sitting systolic blood pressure
|
Baseline, Week 8
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Chang Gyu Park, M.D., Ph.D, Korea University Guro Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
April 1, 2024
Primary Completion (Estimated)
February 1, 2025
Study Completion (Estimated)
February 1, 2025
Study Registration Dates
First Submitted
April 1, 2024
First Submitted That Met QC Criteria
April 1, 2024
First Posted (Actual)
April 4, 2024
Study Record Updates
Last Update Posted (Actual)
April 4, 2024
Last Update Submitted That Met QC Criteria
April 1, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AD-209P3
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension,Essential
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Addpharma Inc.Completed
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
BayerCompletedHypertension, EssentialGermany
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
Addpharma Inc.Not yet recruitingHypertension,Essential
-
Instituto de Cardiologia do Rio Grande do SulRecruitingHypertension | Hypertension,EssentialBrazil
-
Federal University of Health Science of Porto AlegreIrmandade Santa Casa de Misericórdia de Porto Alegre; Leonhardt Ventures LLCNot yet recruitingHypertension | Hypertension,Essential
Clinical Trials on AD-209
-
Addpharma Inc.Completed
-
Nouscom SRLMerck Sharp & Dohme LLCRecruitingSolid Tumor, AdultUnited States, Spain, Italy, Canada, Belgium, United Kingdom
-
Adenovir Pharma ABTFS Trial Form SupportCompletedViral ConjunctivitisGermany, Poland, Sweden
-
Addpharma Inc.Recruiting
-
Addpharma Inc.CompletedHypertensionKorea, Republic of
-
Addpharma Inc.Not yet recruitingHypertension,Essential
-
National Cancer Institute (NCI)RecruitingLynch SyndromeUnited States, Puerto Rico
-
Addpharma Inc.CompletedHyperlipidemiasKorea, Republic of
-
Addpharma Inc.Completed
-
Orion Corporation, Orion PharmaCompletedAdvanced Breast Cancer | Metastatic Breast Cancer | Castration-resistant Prostate Cancer | Prostate Cancer MetastaticFinland, France, Denmark